513 related articles for article (PubMed ID: 16182573)
1. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany.
Opp J; Tuxhorn I; May T; Kluger G; Wiemer-Kruel A; Kurlemann G; Gross-Selbeck G; Rating D; Brandl U; Bettendorf U; Härtel C; Korn-Merker E
Seizure; 2005 Oct; 14(7):476-84. PubMed ID: 16182573
[TBL] [Abstract][Full Text] [Related]
2. Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland.
Steinhoff BJ; Trinka E; Wieser HG;
Seizure; 2005 Oct; 14(7):490-6. PubMed ID: 16169256
[TBL] [Abstract][Full Text] [Related]
3. [Experience with levetiracetam in childhood epilepsy].
Neuwirth M; Saracz J; Hegyi M; Paraicz E; Kollár K; Móser J; Rosdy B; Herczegfalvi A; Fogarasi A
Ideggyogy Sz; 2006 May; 59(5-6):179-82. PubMed ID: 16786712
[TBL] [Abstract][Full Text] [Related]
4. Retention rate of levetiracetam in children with intractable epilepsy at 1 year.
Peake D; Mordekar S; Gosalakkal J; Mukhtyar B; Buch S; Crane J; Wheway R; Rittey C; Donnelly J; Whitehouse WP; Philip S
Seizure; 2007 Mar; 16(2):185-9. PubMed ID: 17258474
[TBL] [Abstract][Full Text] [Related]
5. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
Abou-Khalil B; Hemdal P; Privitera MD
Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
[TBL] [Abstract][Full Text] [Related]
6. Long-term use of Levetiracetam in patients with severe childhood-onset epilepsy.
von Stuelpnagel C; Holthausen H; Kluger G
Eur J Paediatr Neurol; 2007 Nov; 11(6):341-5. PubMed ID: 17442601
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy.
Grosso S; Cordelli DM; Franzoni E; Coppola G; Capovilla G; Zamponi N; Verrotti A; Morgese G; Balestri P
Seizure; 2007 Jun; 16(4):345-50. PubMed ID: 17368928
[TBL] [Abstract][Full Text] [Related]
8. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison.
Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
Seizure; 2008 Jan; 17(1):19-26. PubMed ID: 17618131
[TBL] [Abstract][Full Text] [Related]
10. Levetiracetam in children with refractory epilepsy: lack of correlation between plasma concentration and efficacy.
Giroux PC; Salas-Prato M; Théorêt Y; Carmant L
Seizure; 2009 Oct; 18(8):559-63. PubMed ID: 19546014
[TBL] [Abstract][Full Text] [Related]
11. Levetiracetam for people with mental retardation and refractory epilepsy.
Kelly K; Stephen LJ; Brodie MJ
Epilepsy Behav; 2004 Dec; 5(6):878-83. PubMed ID: 15582836
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of levetiracetam in children younger than 4 years: a retrospective review.
Perry MS; Benatar M
Epilepsia; 2007 Jun; 48(6):1123-7. PubMed ID: 17430408
[TBL] [Abstract][Full Text] [Related]
13. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
Callenbach PM; Arts WF; ten Houten R; Augustijn P; Gunning WB; Peeters EA; Weber AM; Stroink H; Geerts Y; Geerts AT; Brouwer OF
Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.
Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ
Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of levetiracetam efficacy in epileptic syndromes with continuous spikes-waves during slow sleep.
Atkins M; Nikanorova M
Seizure; 2011 Oct; 20(8):635-9. PubMed ID: 21752673
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of add-on levetiracetam in refractory childhood epilepsy.
Kanemura H; Sano F; Tando T; Sugita K; Aihara M
Brain Dev; 2013 May; 35(5):386-91. PubMed ID: 22871391
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of levetiracetam (keppra) add-on treatment in adult patients with refractory epilepsy in two tertiary centers].
Auriel E; Chistik V; Blatt I; Margolin N; Neufeld M
Harefuah; 2007 Apr; 146(4):269-71, 318. PubMed ID: 17476932
[TBL] [Abstract][Full Text] [Related]
18. Loss of the initial efficacy of levetiracetam in patients with refractory epilepsy.
Lee GH; Kim BM; Kang JK; Lee SA
Seizure; 2013 Apr; 22(3):185-8. PubMed ID: 23280273
[TBL] [Abstract][Full Text] [Related]
19. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
Epilepsy Behav; 2007 Mar; 10(2):296-303. PubMed ID: 17317325
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy.
Grosso S; Franzoni E; Coppola G; Iannetti P; Verrotti A; Cordelli DM; Marchiani V; Pascotto A; Spalice A; Acampora B; Morgese G; Balestri P
Seizure; 2005 Jun; 14(4):248-53. PubMed ID: 15911359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
